Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization

Pediatr Allergy Immunol. 2019 Jun;30(4):491-494. doi: 10.1111/pai.13049. Epub 2019 Apr 29.

Authors

Esozia Arroabarren¹, Elena Aznal², Marta Anda¹, Felix Sanchez-Valverde²

Affiliations

¹ Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain.
² Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain.

PMID: 30817035
DOI: 10.1111/pai.13049

No abstract available

Keywords: breakthrough reactions; child; desensitization; elosulfase; mucopolysaccharidosis IV A; omalizumab.

Publication types

Case Reports
Letter

MeSH terms

Allergens / immunology
Anaphylaxis / diagnosis*
Basophil Degranulation Test
Child, Preschool
Chondroitinsulfatases / adverse effects*
Chondroitinsulfatases / immunology
Chondroitinsulfatases / therapeutic use
Desensitization, Immunologic / methods*
Drug Hypersensitivity / diagnosis*
Enzyme Replacement Therapy / adverse effects*
Humans
Immune Tolerance
Immunoglobulin E / metabolism
Injection Site Reaction / diagnosis*
Male
Mucopolysaccharidosis IV
Omalizumab / therapeutic use*
Skin Tests
Urticaria

Substances

Allergens
Omalizumab
Immunoglobulin E
Chondroitinsulfatases
GALNS protein, human